
Regulatory updateRetina
Faricimab: start with the current EU product information
The EMA Vabysmo record is the authoritative entry point for EU product information, assessment documents and authorised indications.
Drug and device decisions, by country and authority.
2 results

The EMA Vabysmo record is the authoritative entry point for EU product information, assessment documents and authorised indications.

From 28 May 2026, mandatory use applies to actor registration, UDI/device registration, notified bodies and certificates, and market surveillance.